Copyright © 2009 David M. Mintzer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. P. A. Arndt and G. Garratty, “The changing spectrum of drug-induced immune hemolytic anemia,” Seminars in Hematology, vol. 42, no. 3, pp. 137–144, 2005. View at Publisher · View at Google Scholar
2. S. T. Johnson, J. T. Fueger, and J. L. Gottschall, “One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia—a new paradigm,” Transfusion, vol. 47, no. 4, pp. 697–702, 2007. View at Publisher · View at Google Scholar · View at PubMed
3. A. R. Gaines, “Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following ${\text{Rh}}_{\text{o}}$(D) immune globulin intravenous administration for immune thrombocytopenic purpura,” Blood, vol. 106, no. 5, pp. 1532–1537, 2005. View at Publisher · View at Google Scholar · View at PubMed
4. G. Borthakur, S. O'Brien, W. G. Wierda, et al., “Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab—incidence and predictors,” British Journal of Haematology, vol. 136, no. 6, pp. 800–805, 2007. View at Publisher · View at Google Scholar · View at PubMed
5. E. Beuter, “G6PD deficiency,” Blood, vol. 84, pp. 3613–3636, 1994.
6. J. G. McHutchison, M. P. Manns, R. S. Brown, Jr., K. R. Reddy, M. L. Shiffman, and J. B. Wong, “Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy,” American Journal of Gastroenterology, vol. 102, no. 4, pp. 880–889, 2007. View at Publisher · View at Google Scholar · View at PubMed
7. M. D. Coleman and N. A. Coleman, “Drug-induced methaemoglobinaemia treatment issues,” Drug Safety, vol. 14, no. 6, pp. 394–405, 1996.
8. J. S. Daly, D. E. Hultquist, and D. L. Rucknagel, “Phenazopyridine induced methaemoglobinaemia associated with decreased activity of erythrocyte cytochrome b5 reductase,” Journal of Medical Genetics, vol. 20, no. 4, pp. 307–309, 1983.
9. K. E. Ward and M. W. McCarthy, “Dapsone-induced methemoglobinemia,” Annals of Pharmacotherapy, vol. 32, no. 5, pp. 549–553, 1998. View at Publisher · View at Google Scholar
10. R. Ash-Bernal, R. Wise, and S. M. Wright, “Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals,” Medicine, vol. 83, no. 5, pp. 265–273, 2004. View at Publisher · View at Google Scholar
11. J. F. Collins, “Methemoglobinemia as a complication of 20% benzocaine spray for endoscopy,” Gastroenterology, vol. 98, no. 1, pp. 211–213, 1990.
12. M. S. Srikanth, R. Kahlstrom, K. H. Oh, S. R. Fox, E. R. Fox, and K. M. Fox, “Topical benzocaine (Hurricaine) induced methemoglobinemia during endoscopic procedures in gastric bypass patients,” Obesity Surgery, vol. 15, no. 4, pp. 584–590, 2005. View at Publisher · View at Google Scholar
13. G. C. Kane, S. M. Hoehn, T. R. Behrenbeck, and S. L. Mulvagh, “Benzocaine-induced methemoglobinemia based on the Mayo Clinic Experience from 28, 478 transesophageal echocardiograms: incidence, outcomes, and predisposing factors,” Archives of Internal Medicine, vol. 167, no. 18, pp. 1977–1982, 2007. View at Publisher · View at Google Scholar · View at PubMed
14. J. M. Scott and D. G. Weir, “Drug-induced megaloblastic change,” Clinics in Haematology, vol. 9, no. 3, pp. 587–606, 1980.
15. A. Bellou, I. Aimone-Gastin, J.-D. De Korwin, et al., “Cobalamin deficiency with megaloblastic anaemia in one patient under long-term omeprazole therapy,” Journal of Internal Medicine, vol. 240, no. 3, pp. 161–164, 1996.
16. J. M. Ruscin, R. L. Page, II, and R. J. Valuck, “Vitamin B12 deficiency associated with histamine2-receptor antagonists and a proton-pump inhibitor,” Annals of Pharmacotherapy, vol. 36, no. 5, pp. 812–816, 2002.
17. T. Alcindor and K. R. Bridges, “Sideroblastic anaemias,” British Journal of Haematology, vol. 116, no. 4, pp. 733–743, 2002. View at Publisher · View at Google Scholar
18. R. A. Sharp, J. G. Lowe, and R. N. Johnston, “Anti-tuberculous drugs and sideroblastic anaemia,” British Journal of Clinical Practice, vol. 44, no. 12, pp. 706–707, 1990.
19. M. C. Montpetit, J. L. Shammo, J. Loew, S. Dunlap, S. V. Pamboukian, and A. Heroux, “Sideroblastic anemia due to linezolid in a patient with a left ventricular assist device,” Journal of Heart and Lung Transplantation, vol. 23, no. 9, pp. 1119–1122, 2004. View at Publisher · View at Google Scholar · View at PubMed
20. L. Condamine, O. Hermine, P. Alvin, M. Levine, C. Rey, and V. Courtecuisse, “Acquired sideroblastic anaemia during treatment of Wilson's disease with triethylene tetramine dihydrochloride,” British Journal of Haematology, vol. 83, no. 1, pp. 166–168, 1993.
21. L. Kandola, A. J. Swannell, and A. Hunter, “Acquired sideroblastic anaemia associated with penicillamine therapy for rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 54, no. 6, pp. 529–530, 1995.
22. M. Kitahara, T. M. Cosgriff, and E. Harmon, “Sideroblastic anemia as a preleukemic event in patients treated for Hodgkin's disease,” Annals of Internal Medicine, vol. 92, pp. 625–627, 1980.
23. N. S. Young, R. T. Calado, and P. Scheinberg, “Current concepts in the pathophysiology and treatment of aplastic anemia,” Blood, vol. 108, no. 8, pp. 2509–2519, 2006. View at Publisher · View at Google Scholar · View at PubMed
24. M. Aksoy, S. Erdem, G. Dincol, I. Bakioglu, and A. Kutlar, “Aplastic anemia due to chemicals and drugs: a study of 108 patients,” Sexually Transmitted Disease, vol. 11, pp. 347–350, 1984.
25. R. Andrews and N. Russell, “Aplastic anemia associated with a non-steroidal anti-inflammatory drug: relapse after exposure to another such drug,” British Medical Journal, vol. 301, p. 38, 1990.
26. M. N. Alnigenis, M. Nalcaci, Y. Pekcelen, T. Atamer, and D. Sargin, “Possible etiologic factors in 151 Turkish patients with aplastic anemia,” American Journal of Hematology, vol. 68, no. 1, pp. 60–61, 2001. View at Publisher · View at Google Scholar · View at PubMed
27. E. Baumelou, M. Guiguet, and J. Y. Mary, “Epidemiology of aplastic anemia in France: a case-control study,” Blood, vol. 81, no. 6, pp. 1471–1478, 1993.
28. R. Smalling, M. Foote, G. Molineux, S. J. Swanson, and S. Elliott, “Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge,” Biotechnology Annual Review, vol. 10, pp. 237–249, 2004. View at Publisher · View at Google Scholar · View at PubMed
29. N. Tanaka, F. Ishida, and E. Tanaka, “Ribavirin-induced pure red-cell aplasia during treatment of chronic hepatitis C,” The New England Journal of Medicine, vol. 350, no. 12, pp. 1264–1265, 2004. View at Publisher · View at Google Scholar · View at PubMed
30. N. Casadevall, J. Nataf, B. Viron, et al., “Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin,” The New England Journal of Medicine, vol. 346, no. 7, pp. 469–475, 2002. View at Publisher · View at Google Scholar · View at PubMed
31. S. A. Summers, A. Matijevic, and M. K. Almond, “Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia,” Nephrology Dialysis Transplantation, vol. 19, no. 8, pp. 2137–2139, 2004.
32. D. Verhelst, J. Rossert, N. Casadevall, A. Kruger, K.-U. Eckardt, and I. C. Macdougall, “Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study,” The Lancet, vol. 363, no. 9423, pp. 1768–1771, 2004. View at Publisher · View at Google Scholar · View at PubMed
33. C. L. Bennett, S. Luminari, A. R. Nissenson, et al., “Pure red-cell aplasia and epoetin therapy,” The New England Journal of Medicine, vol. 351, no. 14, pp. 1403–1408, 2004. View at Publisher · View at Google Scholar · View at PubMed
34. R. H. Aster and D. W. Bougie, “Drug-induced immune thrombocytopenia,” The New England Journal of Medicine, vol. 357, no. 6, pp. 580–587, 2007. View at Publisher · View at Google Scholar · View at PubMed
35. G. P. Visentin and C. Y. Liu, “Drug-induced thrombocytopenia,” Hematology/Oncology Clinics of North America, vol. 21, no. 4, pp. 685–696, 2007. View at Publisher · View at Google Scholar · View at PubMed
36. D. W. Bougie, P. R. Wilker, and R. H. Aster, “Patients with quinine-induced immune thrombocytopenia have both “drug-dependent” and “drug-specific” antibodies,” Blood, vol. 108, no. 3, pp. 922–927, 2006. View at Publisher · View at Google Scholar · View at PubMed
37. A. von Drygalski, B. R. Curtis, D. W. Bougie, et al., “Vancomycin-induced immune thrombocytopenia,” The New England Journal of Medicine, vol. 356, no. 9, pp. 904–910, 2007. View at Publisher · View at Google Scholar · View at PubMed
38. G. M. Arepally and T. L. Ortel, “Heparin-induced thrombocytopenia,” The New England Journal of Medicine, vol. 355, no. 8, pp. 809–817, 2006. View at Publisher · View at Google Scholar · View at PubMed
39. T. E. Wartenkin, “Heparin-induced thrombocytopenia,” Hematology/Oncology Clinics of North America, vol. 21, pp. 589–607, 2007.
40. R. H. Aster, B. R. Curtis, and D. W. Bougie, “Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors,” Seminars in Thrombosis and Hemostasis, vol. 30, no. 5, pp. 569–577, 2004. View at Publisher · View at Google Scholar · View at PubMed
41. R. Pisoni, P. Ruggenenti, and G. Remuzzi, “Drug-induced thrombotic microangiopathy: incidence, prevention and management,” Drug Safety, vol. 24, no. 7, pp. 491–501, 2001.
42. A. Zakarija and C. Bennett, “Drug-induced thrombotic microangiopathy,” Seminars in Thrombosis and Hemostasis, vol. 31, no. 6, pp. 681–690, 2005. View at Publisher · View at Google Scholar · View at PubMed
43. P. J. Medina, J. M. Sipols, and J. N. George, “Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome,” Current Opinion in Hematology, vol. 8, no. 5, pp. 286–293, 2001. View at Publisher · View at Google Scholar
44. C. L. Bennett, B. Kim, A. Zakarija, et al., “Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura. A report from the SERF-TTP Research Group and the RADAR Project,” Journal of the American College of Cardiology, vol. 50, no. 12, pp. 1138–1143, 2007. View at Publisher · View at Google Scholar · View at PubMed
45. K. Kojouri, S. K. Vesely, and J. N. George, “Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes,” Annals of Internal Medicine, vol. 135, no. 12, pp. 1047–1051, 2001.
46. S. Tseeng and R. Arora, “Reviews: aspirin resistance: biological and clinical implications,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 13, no. 1, pp. 5–12, 2008. View at Publisher · View at Google Scholar · View at PubMed
47. Y.-M. P. Shen and E. P. Frenkel, “Acquired platelet dysfunction,” Hematology/Oncology Clinics of North America, vol. 21, no. 4, pp. 647–661, 2007. View at Publisher · View at Google Scholar · View at PubMed
48. D. Mukherjee, S. E. Nissen, and E. J. Topol, “Risk of cardiovascular events associated with selective COX-2 inhibitors,” Journal of the American Medical Association, vol. 286, no. 8, pp. 954–959, 2001.
49. P. M. Kearney, C. Baigent, J. Godwin, H. Halls, J. R. Emberson, and C. Patrono, “Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials,” British Medical Journal, vol. 332, no. 7553, pp. 1302–1305, 2006.
50. D. J. Kerr, J. A. Dunn, M. J. Langman, et al., “Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer,” The New England Journal of Medicine, vol. 357, no. 4, pp. 360–369, 2007. View at Publisher · View at Google Scholar · View at PubMed
51. A. K. Singh, L. Szczech, K. L. Tang, et al., “Correction of anemia with epoetin alfa in chronic kidney disease,” The New England Journal of Medicine, vol. 355, no. 20, pp. 2085–2098, 2006. View at Publisher · View at Google Scholar · View at PubMed
52. J. Bohlius, J. Wilson, J. Seidenfeld, et al., “Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients,” Journal of the National Cancer Institute, vol. 98, no. 10, pp. 708–714, 2006. View at Publisher · View at Google Scholar · View at PubMed
53. J. P. Vandenbroucke, J. Rosing, K. W. M. Bloemenkamp, et al., “Oral contraceptives and the risk of venous thrombosis,” The New England Journal of Medicine, vol. 344, no. 20, pp. 1527–1535, 2001. View at Publisher · View at Google Scholar
54. M. Cushman, L. H. Kuller, R. Prentice, et al., “Estrogen plus progestin and risk of venous thrombosis,” Journal of the American Medical Association, vol. 292, no. 13, pp. 1573–1580, 2004. View at Publisher · View at Google Scholar · View at PubMed
55. V. G. Vogel, J. P. Costantino, D. L. Wickerham, et al., “Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial,” Journal of the American Medical Association, vol. 295, no. 23, pp. 2727–2741, 2006. View at Publisher · View at Google Scholar · View at PubMed
56. A. Howell, J. Cuzick, and M. Baum, “Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer,” The Lancet, vol. 365, pp. 60–62, 2005. View at Publisher · View at Google Scholar
57. J. S. Rogers, II, A. J. Murgo, J. A. Fontana, and P. C. Raich, “Chemotherapy for breast cancer decreases plasma protein C and protein S,” Journal of Clinical Oncology, vol. 6, no. 2, pp. 276–281, 1988.
58. T. Saphner, D. C. Tormey, and R. Gray, “Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer,” Journal of Clinical Oncology, vol. 9, no. 2, pp. 286–294, 1991.
59. K. I. Pritchard, A. H. G. Paterson, N. A. Paul, B. Zee, S. Fine, and J. Pater, “Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer,” Journal of Clinical Oncology, vol. 14, no. 10, pp. 2731–2737, 1996.
60. S. R. Alberts, M. Bretscher, J. C. Wiltsie, B. P. O'Neill, B. Mokri, and T. E. Witzig, “Thrombosis related to the use of L-asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement,” Leukemia and Lymphoma, vol. 32, no. 5-6, pp. 489–496, 1999.
61. J. H. Payne and A. Vora, “Thrombosis and acute lymphoblastic leukaemia,” British Journal of Haematology, vol. 138, pp. 430–445, 2007.
62. V. Caruso, L. Iacoviello, A. Di Castelnuovo, et al., “Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients,” Blood, vol. 108, no. 7, pp. 2216–2222, 2006. View at Publisher · View at Google Scholar · View at PubMed
63. A. Palumbo, S. V. Rajkumar, M. A. Dimopoulos, et al., “Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma,” Leukemia, vol. 22, no. 2, pp. 414–423, 2008. View at Publisher · View at Google Scholar · View at PubMed
64. Y. C. Chan, D. Valenti, A. O. Mansfield, and G. Stansby, “Warfarin induced skin necrosis,” British Journal of Surgery, vol. 87, no. 3, pp. 266–272, 2000. View at Publisher · View at Google Scholar · View at PubMed
65. T. E. Warkentin, R. S. Roberts, J. Hirsh, and J. G. Kelton, “Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study,” Chest, vol. 127, no. 5, pp. 1857–1861, 2005. View at Publisher · View at Google Scholar · View at PubMed
66. F. A. Scappaticci, J. R. Skillings, S. N. Holden, et al., “Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab,” Journal of the National Cancer Institute, vol. 99, no. 16, pp. 1232–1239, 2007. View at Publisher · View at Google Scholar · View at PubMed
67. M. Franchini, F. Capra, N. Nicolini, et al., “Drug-induced anti-factor VIIII antibodies: a systematic review,” Medical Science Monitor, vol. 13, pp. 55–61, 2007. View at Publisher · View at Google Scholar · View at PubMed
68. P. T. Otis, D. I. Feinstein, S. I. Rapaport, and M. J. Patch, “An acquired inhibitor of fibrin stabilization associated with isoniazid therapy: clinical and biochemical observations,” Blood, vol. 44, no. 6, pp. 771–781, 1974.
69. S. Austin and H. Cohen, “Antiphospholipid syndrome,” Medicine, vol. 34, no. 11, pp. 472–475, 2006. View at Publisher · View at Google Scholar
70. S. Clauser, A. Fischer, and L. Darnige, “Quinine-induced lupus anticoagulant, hypoprothrombinemia, and antiprothrombin antibodies,” American Journal of Hematology, vol. 82, p. 330, 2007.
71. Y. M. Shevchuk and J. M. Conly, “Antibiotic-associated hypoprothrombinemia: a review of prospective studies, 1966–1988,” Reviews of Infectious Diseases, vol. 12, no. 6, pp. 1109–1126, 1990.
72. B. L. Strom, R. Schinnar, G. A. Gibson, P. J. Brennan, and J. A. Berlin, “Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: using cefoperazone as a test case,” Pharmacoepidemiology and Drug Safety, vol. 8, no. 2, pp. 81–94, 1999. View at Publisher · View at Google Scholar
73. A. M. Holbrook, J. A. Pereira, R. Labiris, et al., “Systematic overview of warfarin and its drug and food interactions,” Archives of Internal Medicine, vol. 165, no. 10, pp. 1095–1106, 2005. View at Publisher · View at Google Scholar · View at PubMed
74. V. Bhatt and A. Saleem, “Drug-induced neutropenia—pathophysiology, clinical features, and management,” Annals of Clinical and Laboratory Science, vol. 34, no. 2, pp. 131–137, 2004.
75. N. Tavassoli, E. Duchayne, B. Sadaba, et al., “Detection and incidence of drug-induced agranulocytosis in hospital: a prospective analysis from laboratory signals,” European Journal of Clinical Pharmacology, vol. 63, no. 3, pp. 221–228, 2007. View at Publisher · View at Google Scholar · View at PubMed
76. F. Andersohn, C. Konzen, and E. Garbe, “Systematic review: agranulocytosis induced by nonchemotherapy drugs,” Annals of Internal Medicine, vol. 146, no. 9, pp. 657–665, 2007.
77. K. Chaiwatanatorn, N. Lee, A. Grigg, R. Filshie, and F. Firkin, “Delayed-onset neutropenia associated with rituximab therapy,” British Journal of Haematology, vol. 121, no. 6, pp. 913–918, 2003. View at Publisher · View at Google Scholar
78. D. C. Dale, As. Fauci, D. Guerry, and S. M. Wolff, “Comparison of agents producing a neutrophilic leukocytosis in man,” Journal of Clinical Investigation, vol. 56, pp. 808–813, 1975.
79. Y. Shoenfeld, Y. Gurewich, L. A. Gallant, and J. Pinkhas, “Prednisone-induced leukocytosis. Influence of dosage, method and duration of administration on the degree of leukocytosis,” American Journal of Medicine, vol. 71, no. 5, pp. 773–778, 1981.
80. S. Roath, D. Choudhury, J. G. Edwards, J. L. Francis, and A. Gordon, “Neutrophil mobilization in lithium-induced neutrophilia,” Human Psychopharmacology, vol. 2, pp. 237–241, 2004.
81. P. R. Cohen, “Sweet's syndrome—a comprehensive review of an acute febrile neutrophilic dermatosis,” Orphanet Journal of Rare Diseases, vol. 2, no. 1, p. 34, 2007. View at Publisher · View at Google Scholar · View at PubMed
82. A. Tefferi, M. M. Patnaik, and A. Pardanani, “Eosinophilia: secondary, clonal and idiopathic,” British Journal of Haematology, vol. 133, no. 5, pp. 468–492, 2006. View at Publisher · View at Google Scholar · View at PubMed
83. S. Tas and T. Simonart, “Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update,” Dermatology, vol. 206, no. 4, pp. 353–356, 2003. View at Publisher · View at Google Scholar · View at PubMed
84. N. Robinson, S. Giraud, C. Saudan, et al., “Erythropoietin and blood doping,” British Journal of Sports Medicine, vol. 40, pp. i30–i34, 2006. View at Publisher · View at Google Scholar · View at PubMed
85. N. Mauritzson, M. Albin, L. Rylander, et al., “Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001,” Leukemia, vol. 16, no. 12, pp. 2366–2378, 2002. View at Publisher · View at Google Scholar · View at PubMed
86. S. M. Smith, M. M. Le Beau, D. Huo, et al., “Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series,” Blood, vol. 102, no. 1, pp. 43–52, 2003. View at Publisher · View at Google Scholar · View at PubMed
87. M. Beaumont, M. Sanz, P. M. Carli, et al., “Therapy-related acute promyelocytic leukemia,” Journal of Clinical Oncology, vol. 21, no. 11, pp. 2123–2137, 2003. View at Publisher · View at Google Scholar · View at PubMed
88. R. E. Smith, J. Bryant, A. DeCillis, and S. Anderson, “Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience,” Journal of Clinical Oncology, vol. 21, no. 7, pp. 1195–1204, 2003. View at Publisher · View at Google Scholar
89. D. Hershman, A. I. Neugut, J. S. Jacobson, et al., “Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy,” Journal of the National Cancer Institute, vol. 99, no. 3, pp. 196–205, 2007. View at Publisher · View at Google Scholar · View at PubMed
90. D. A. Patt, Z. Duan, S. Fang, G. N. Hortobagyi, and S. H. Giordano, “Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk,” Journal of Clinical Oncology, vol. 25, no. 25, pp. 3871–3876, 2007. View at Publisher · View at Google Scholar · View at PubMed
91. J. Pedersen-Bjergaard, M. K. Andersen, and D. H. Christiansen, “Therapy-related acute myeloid leukemia and myelodysplasia after high- dose chemotherapy and autologous stem cell transplantation,” Blood, vol. 95, no. 11, pp. 3273–3279, 2000.
92. K. S. Baker, T. E. DeFor, L. J. Burns, N. K. C. Ramsay, J. P. Neglia, and L. L. Robison, “New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors,” Journal of Clinical Oncology, vol. 21, no. 7, pp. 1352–1358, 2003. View at Publisher · View at Google Scholar
93. G. J. Roboz, J. M. Bennett, M. Coleman, et al., “Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma,” Leukemia Research, vol. 31, no. 8, pp. 1141–1144, 2007. View at Publisher · View at Google Scholar · View at PubMed
94. J. Lazarou, B. H. Pomeranz, and P. N. Corey, “Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies,” Journal of the American Medical Association, vol. 279, no. 15, pp. 1200–1205, 1998. View at Publisher · View at Google Scholar
95. A. K. Jha, G. J. Kuperman, E. Rittenberg, J. M. Teich, and D. W. Bates, “Identifying hospital admissions due to adverse drug events using a computer-based monitor,” Pharmacoepidemiology and Drug Safety, vol. 10, no. 2, pp. 113–119, 2001. View at Publisher · View at Google Scholar · View at PubMed